pdufa date for tirzepatide Lilly to launch Zepbound in more markets this year; Casgevy bags second FDA nod FDA PDUFA Calendar, PDUFA Dates,

Data availability The data underlying this article are available in NAHNES website, at [ Abbreviations ASCVD: Atherosclerotic cardiovascular disease BMI: Body mass index BRC: Biomedical Research Centre CAD: Coronary artery disease CDC: Centers for Disease Control and Prevention CI: Confidence interval CKD: Chronic kidney disease CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration CVD: Cardiovascular disease eGFR: Estimated glomerular filtration rate FDA: Food and Drug Administration GLP-1: Glucagon-like peptide-1 GLP-1 RA: Glucagon-like peptide-1 receptor agonist HbA1c: Glycated haemoglobin HR: Hazard ratio IQR: Interquartile range KDIGO: Kidney disease: improving global outcomes MACE: Major adverse cardiovascular events MEC: Mobile Examination Center MI: Myocardial infarction NCHS: National Center for Health Statistics NHANES: National Health and Nutrition Examination Survey NIHR: National Institute for Health and Care Research NNT: Number needed to treat PAD: Peripheral artery disease SOUL: Semaglutide Cardiovascular Outcomes Trial U.S.: United States UK: United Kingdom References Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al

2022 Nov 9;5(4):311-331

The high efficacy of both Zepbound and Wegovy means competition shifts to price transparency and affordability, leading to the Zepbound cost reduction Chicago and the discounted Semaglutide price changes Chicago making them both highly affordable weight loss medications Chicago

Discontinuation due to adverse events was 6%, lower than either Semaglutide or Retatrutide at maximum doses